Dopaminergic Pharmacology, Neurodegenerative Diseases, and TTR Stabilizers – Lecture Notes

Announcements and Exam Scope

• Virtual discussions confirmed; no in-person requirement.
• Assignment posted yesterday; due next Monday; virtual discussion with Dr. Thomas too; no on-site presence for discussion.
• Exam scope: any material discussed up to today is included in the Friday exam; regardless of topic.
• If questions arise, focus on understanding the content and how it connects across topics.

Adrenergic Antagonists: Alpha and Beta Blockers

• Quinazoline-based drugs (adrenergic antagonists) block adrenergic receptors; structure features include a quinazoline ring. Side-chain variations affect activity and half-life.
• Clinical use: hypertension and benign prostatic hyperplasia (BPH). For patients with both hypertension and BPH, alpha-1 blockers are beneficial because they target alpha-1 receptors in vasculature and prostate.
• Examples discussed: tamsulosin and alpha-1 blockers (alfuzosin, and similar) for prostate issues; selective targeting to avoid unwanted vascular effects in patients without vascular issues.
• Beta blockers overview: molecules that block beta receptors; canonical structure with an aryl group and an amino side chain (often described as an aryl-oxy- propanol-amine framework).
• Classic beta blockers: propranolol and nadolol.
• Similar SCR (structure-activity relationships) exist between propranolol and nadolol; nadolol is more polar than propranolol due to more hydroxyl groups, so it has less CNS penetration.
• Other beta-1 selective blockers include atenolol, betaxolol, bisoprolol; many end with “propranololamine” motif.
• CNS side effects risk: atenolol tends to have fewer CNS side effects than propranolol because of higher polarity.
• Exam tip mentioned: given two beta blockers (e.g., propranolol vs atenolol), identify which has fewer CNS effects by assessing polarity (more polar = less CNS penetration).

Dopaminergic System and Parkinson’s Disease: Core Concepts

• Dopamine basics: a catecholamine CNS neurotransmitter; involved in emotion, movement, and reward.
• Dopamine and disease logic: insufficient dopamine biosynthesis in dopaminergic neurons is linked to Parkinson’s disease; therapies aim to increase dopamine levels or reduce its metabolism.
• Dopamine synthesis pathway (recalled for exam context):
  • Tyrosine → L-DOPA → Dopamine.
  • L-DOPA is a prodrug that crosses the blood–brain barrier (BBB) and is converted to dopamine in the brain.
  • Dopamine is metabolized to inactive products via MAO and COMT.
• Dopamine and movement: dopamine is essential for movement; reduced dopamine leads to Parkinsonian symptoms; conversely, excess dopamine activity can relate to psychosis.
• Dopamine receptors: five dopaminergic GPCRs on the postsynapse; a D2 autoreceptor exists presynaptically; activation of the D2 autoreceptor decreases dopamine release; antagonism or blockade increases dopamine availability.
• Dopamine synthesis and release cycle: dopamine is produced in the presynapse, released into the synapse, binds to receptors, and is cleared by the dopamine transporter (DAT).
• DAT inhibitors and abuse: many drugs of abuse (e.g., amphetamine) block DAT, increasing synaptic dopamine and causing euphoric effects.
• Clinical relevance of synthesis pathways: understanding how synthesis, release, reuptake, and metabolism control dopamine levels helps explain pharmacotherapies and side effects.

Dopamine Metabolism and Lab Markers

• Dopamine metabolism by MAO and COMT (key concepts):
  • MAO oxidizes the amine to an aldehyde.
  • COMT methylates the catechol, facilitating formation of downstream metabolites.
  • End products:
  • For dopamine: homovanillic acid (HVA)
  • For norepinephrine/epinephrine: vanillylmandelic acid (VMA)
• Nomenclature notes from the lecture:
  • “DOBAC” mentioned as an inactive metabolite when the amine is removed; the intended common metabolite discussed is DOPAC, which is then further processed to HVA.
• Clinical lab test relevance (Mayo Clinic context): elevated HVA and VMA in urine can indicate catecholamine-secreting tumors (e.g., neuroblastoma, pheochromocytoma); these metabolites are used for screening and monitoring therapy.
• Key diagnostic point: monitoring HVA and VMA helps assess dopaminergic neuron activity and the metabolic state in catecholamine-related disorders.
• Genetic and metabolic considerations:
  • Monoamine oxidase (MAO) deficiency can reduce HVA levels due to decreased dopamine metabolism.
  • Dopamine beta-hydroxylase deficiency can elevate urinary HVA by redirecting dopamine metabolism.

Parkinson’s Disease Pharmacology: From L-DOPA to Monoamine Modulation

• L-DOPA therapy and pharmacokinetic challenges:
  • L-DOPA is the prodrug that must reach the brain and be converted to dopamine by AADC (dopa decarboxylase).
  • Oral bioavailability of L-DOPA is less than 2% due to peripheral decarboxylation, peripheral metabolism by COMT, and intestinal MAO/COMT activity leading to loss of drug before brain entry.
• The role of carbidopa: peripherally acting AADC inhibitor; does not cross the BBB; increases brain delivery of L-DOPA by preventing peripheral conversion to dopamine.
• The rationale for triple therapy in PD:
  • L-DOPA supplies dopamine (prodrug).
  • Carbidopa inhibits peripheral AADC to spare L-DOPA from peripheral conversion.
  • COMT inhibitors (tolcapone or entacapone) prevent peripheral metabolism of L-DOPA to 3-OMD and HVA, increasing brain delivery and reducing peripheral side effects.
  • Tolcapone crosses BBB and inhibits CNS COMT; entacapone does not cross BBB but has lower hepatotoxic risk.
• COMT inhibitors: tolcapone (binds CNS and periphery) and entacapone (periphery-focused; less hepatotoxicity).
• L-DOPA and the “cheese effect” context: dietary tyramine interactions via MAO inhibition can cause hypertensive crises; MAO inhibitors used in PD require dietary caution.

MAO Inhibitors in PD: Selegiline, Rasagiline, and the Cheese Effect

• MAO enzymes in PD treatment:
  • MAO-A preferentially metabolizes norepinephrine, epinephrine, and serotonin.
  • MAO-B metabolizes dopamine and related phenylethylamines; inhibition increases dopamine availability.
• Selegiline and rasagiline are MAO-B inhibitors used to prolong dopamine action by reducing metabolism.
• The “cheese effect” explained: tyramine (a monoamine found in aged cheese and certain wines) is a substrate for MAO-A and MAO-B, and in peripheral tissue can cause sympathetic stimulation. Nonselective MAO inhibitors raise tyramine levels, risking hypertensive crisis; hence dietary restrictions or selective MAO-B inhibitors at appropriate doses are used to minimize risk.
• Selegiline metabolism and downstream products:
  • Selegiline can be metabolized to amphetamine and methamphetamine derivatives; these metabolites contribute to dopaminergic activity but can cause side effects or abuse potential (the lecture distinguishes the active drug from its metabolites).
• Rasagiline: a selective MAO-B inhibitor with different metabolic profile; the lecture notes its pharmacology compared to selegiline and its potential in combination therapy.
• Important exam point: selective MAO-B inhibitors at appropriate doses minimize cheese effect risk; higher doses may lose selectivity and affect MAO-A as well.

Tyramine, Cheese Effect, and Patient Counseling

• Tyramine structure and relevance: tyramine is a degraded amine found in certain foods (e.g., aged cheeses, red wine).
• Tyramine is not a catechol but is a substrate for MAO-A and MAO-B; it does not undergo COMT inactivation in the same way as catechols do.
• In patients taking MAO inhibitors (nonselective), ingestion of tyramine can elicit strong peripheral sympathetic responses (flushing, hypertension) due to sudden dopamine-like activity in the periphery.
• Counseling takeaway: dietary tyramine can interact with MAO inhibitors; selective MAO-B inhibitors at proper doses have lower risk of cheese effect, but individual metabolic variation can still cause reactions.

Dopamine Agonists in PD: Ergot and Non-Ergot Derivatives

• Direct agonists of dopamine receptors are used when residual dopamine signaling remains after neurodegeneration.
• Two broad classes:
  • Ergot-derived dopamine agonists (natural product alkaloids).
  • Non-ergot dopamine agonists (e.g., apomorphine, pramipexol, ropinirole, etc.; the lecture mentions specific names including apomorphine, ramipixol, andropanol—note: these names reflect the lecture; some may be different in standard nomenclature).
• These agents directly stimulate dopaminergic receptors to compensate for reduced endogenous dopamine.

Alzheimer’s Disease: Context, Plaques, and Therapeutic Avenues

• Brief clinical picture: Alzheimer’s disease is a neurodegenerative disorder characterized by progressive memory loss and cognitive decline.
• Amyloid hypothesis overview discussed: beta-amyloid (Aβ) plaques form from amyloid precursor protein (APP) processing by beta-secretase and gamma-secretase, producing Aβ42, which aggregates to form amyloid plaques.
• Disease challenges: plaques, oligomers, and neurodegeneration drive pathology; there is no disease-modifying cure; current approaches focus on slowing progression or managing symptoms.
• Therapeutic approaches mentioned:
  • Cholinesterase inhibitors (e.g., rivastigmine) to boost acetylcholine signaling and provide some symptomatic relief.
  • Antibody-based therapies targeting amyloid species (monomers or oligomers) to clear aggregates; one antibody-based drug advanced in late-stage development with debate over clinical efficacy and cost.
  • Imaging and early detection: florbetapir (a PET tracer) to visualize amyloid plaques in the brain; enables imaging-based assessment of amyloid burden.
• Lifestyle and neuroprotection theme: sleep, cardiovascular health, exercise, and mental stimulation (neuroplasticity) are emphasized as non-pharmacological strategies to support brain health and potentially delay progression.
• Neuropsychology and public health angle: three practical recommendations for aging individuals include sleep quality, physical activity, and cognitively engaging activities to support brain resilience.

Transthyretin (TTR) Amyloidosis: Stabilizers and Drug Development

• What is TTR? A liver-produced tetrameric protein that transports retinol-binding protein and thyroxine; the brain also makes its own TTR.
• Pathology: destabilization of the TTR tetramer (due to aging or mutations) leads to monomer misfolding and amyloid formation, causing neuropathy and cardiomyopathy. A single amino-acid change can drastically alter stability and disease progression.
• Key mutation and stability concept: T119M mutation in TTR stabilizes the tetramer and is associated with longer lifespan in certain populations; the lecture cites data from European populations showing extended lifespan for carriers of T119M due to increased stability.
• Therapeutic strategy: small-molecule stabilizers bind in the TTR pocket between the dimers and stabilize the tetramer, preventing dissociation and amyloid formation.
• Pfizer’s tafamidis (approved 2019) is a TTR stabilizer that reduces tetramer destabilization but, per the lecture, stabilizes about 50% of TTR in the tested context.
• AG10 (referred to as AGitin in the talk) is a stabilizer designed to mimic the protective effect of the T119M mutation by forming additional stabilizing interactions (hydrogen bonds and salt bridges) in the TTR pocket.
• Structural insights from crystal data (2013) and subsequent work:
  • Pfizer’s tafamidis forms some stabilizing interactions but may lack certain bottom-pocket interactions compared to AG10.
  • AG10 forms two salt bridges with lysine residues and two hydrogen bonds with serine residues, providing stronger stabilization in the pocket between TTR dimers.
  • The engineered stabilization by AG10 yielded stabilization of a large majority (>95%) of TTR in vitro, compared to ~50% stabilization by tafamidis.
• Development timeline and clinical impact:
  • The journey from discovery to clinical impact spans many years (2008–2024 in the talk): early discovery of stabilizers, academic–industry collaboration, and eventual clinical trials and regulatory approval.
  • In the talk, a company effort culminated in a phase-3 program with successful results published in the New England Journal of Medicine, followed by FDA approval in 2024 for the stabilizer (brand name Atrobi in the talk’s context).
  • Market context: rare diseases (orphan indications) can attract high per-patient pricing; Pfizer’s tafamidis had been a major competitor with high annual cost. The speaker emphasizes broader access and affordability over time as patents expire and competition increases.
• Broader implications: stabilizing TTR to prevent amyloid formation could slow or prevent disease progression in transthyretin-related amyloidoses; the case highlights the value of targeted protein stabilization strategies and the potential for genetic variants (like T119M) to inform drug design.

Integrative Notes: Real-World Contexts and Exam-Oriented Takeaways

• The lecture intertwines chemistry, pharmacology, and clinical relevance: understanding chemical structures, receptor interactions, and metabolic pathways is essential to rational drug design and patient care.
• Exam-oriented strategies highlighted in the talk include:
  • Compare beta-blockers based on CNS penetration by analyzing polarity and logP tendencies.
  • Identify which PD therapies act peripherally vs centrally (e.g., carbidopa blocks peripheral AADC; tolcapone/entacapone inhibit COMT; MAO-B inhibitors modify dopamine metabolism without causing excessive peripheral activation if dosed carefully).
  • Predict CNS side effects and interactions (e.g., atenolol vs propranolol, MPTP story, cheese effect with MAO inhibitors).
  • Recognize that L-DOPA requires combination therapy to maximize brain delivery and minimize peripheral side effects; explain why each component (L-DOPA, carbidopa, COMT inhibitors) is used.
  • Understand the MPTP story as a teaching example of how environmental neurotoxins helped establish the dopaminergic basis of PD and how therapeutic strategies evolved in response.
  • Grasp the rationale behind TTR stabilizers and how stabilizing interactions (salt bridges, hydrogen bonds) can dramatically influence protein stability and disease outcomes; compare tafamidis with AG10 in terms of structural stabilization and potential clinical impact.
• Ethical and practical implications discussed:
  • The professor’s reflections on pharmaceutical industry practices and drug pricing illustrate the tension between innovation, access, and corporate strategy.
  • Emphasis on using AI and modern resources wisely in clinical chemistry; the importance of critical thinking and resource curation when approaching complex data.
• Key numerical and structural references to remember:
  • Parkinson’s disease is associated with the loss of about 75% of dopaminergic neurons before symptoms manifest.
  • L-DOPA oral bioavailability: < 2% without combination therapy.
  • Endogenous transport and metabolism considerations influence drug design (AADC, COMT, MAO, DAT).
  • Therapies discussed include:
  • L-DOPA (prodrug) and peripheral AADC inhibitor (carbidopa) to improve brain delivery.
  • COMT inhibitors: tolcapone (CNS + periphery) and entacapone (periphery; less hepatotoxicity).
  • MAO inhibitors: selegiline (MAO-B selective at low dose) and rasagiline (selective MAO-B inhibitor).
  • Dopamine agonists: ergot and non-ergot classes (examples noted in lecture).
  • Cholinesterase inhibitors for Alzheimer’s symptoms and antibody strategies for amyloid clearance.
  • TTR stabilizers: tafamidis (Pfizer) vs AG10 (AGitin) stabilization approaches; the potential for strong stabilization correlates with clinical efficacy.

Quick Recap and Key Formulas

• Dopamine biosynthesis (conceptual):
  • Tyrosine
  • ext{Tyrosine}
    ightarrow ext{L-DOPA}
    ightarrow ext{Dopamine}
• Blood–brain barrier considerations and prodrugs:
  • ext{L-DOPA} ext{ crosses BBB}
    ightarrow ext{Dopamine} ext{ in brain}
  • Dopamine itself cannot cross BBB efficiently.
• L-DOPA pharmacology: combination therapy rationale
  • ext{L-DOPA} ext{ bioavailability} < 2 ext{ extpercent}
  • Peripheral decarboxylation and MAO/COMT metabolism reduce brain delivery.
• Key metabolism products:
  • Dopamine
  • ext{DOPAC}
    ightarrow ext{HVA (homovanillic acid)}
  • Norepinephrine/Epinephrine → $ext{VMA (vanillylmandelic acid)}$
• MPTP story (conceptual):
  • ext{MPTP}
    ightarrow ext{MPP}^+ ext{ (via MAO-B)}
    ightarrow ext{dopaminergic neuron death}
• TTR stabilization concept (structural):
  • AG10 forms {
    salt bridges with Lys residues; hydrogen bonds with Ser residues
    } enabling >95% stabilization in vitro vs ~50% for tafamidis.
• Timeline anchors (per talk):
  • Tafamidis approved by Pfizer in 2019; AG10/AGitin work leading to late-stage progress; FDA approval and brand Atrobi mentioned around 2024.

Quotes and Personal Insights (for exam reflections)

• The lecturer emphasizes that teaching organic chemistry can become intuitive when you visualize structures and mechanisms; real-world examples (MPTP, Parkinson’s, and bitter industry politics) illustrate the importance of chemistry in medicine.
• Ethical and professional reminders: use AI responsibly, verify sources, and develop skills to interpret data and defend clinical decisions.
• The overarching goal is to improve patient outcomes through rational drug design and careful consideration of metabolism, distribution, and safety profiles.

End of Notes